{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Myocardial Infarction",
            "NStudiesAvail": 430108,
            "NStudiesFound": 46,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 46,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "MACE was defined as the composites of any cause of death, myocardial infarction, revascularization of the target vessel, re-hospitalization for heart failure, and life-threatening arrhythmia."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes in left ventricular end-diastolic volume (LVEDV)",
                              "Changes in left ventricular end-systolic volume (LVESV)",
                              "Changes in regional wall motion score index (WMSI) by Echocardiography",
                              "Major adverse cardiac event (MACE)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline and 6 months",
                              "baseline and 6 months",
                              "baseline and 6 months",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01392105"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "incidence of cardiovascular events",
                              "overall mortality",
                              "adverse events at 12 months after transplantation of autologous BM-MSCs"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "incidence of cardiovascular events",
                              "overall mortality",
                              "adverse events at 12 months after transplantation of autologous BM-MSCs"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "in 12 months after transplantation of autologous BM-MSCs",
                              "in 12 months after transplantation of autologous BM-MSCs",
                              "in 12 months after transplantation of autologous BM-MSCs"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04421274"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Safety will be determined by the assessment of major adverse coronary events (MACE) defined as cardiac death, peri-procedural myocardial infarction, or any repeat coronary intervention at 4 months-1year. Furthermore, safety is also determined by the occurrence of stent thrombosis, arrhythmias events. immune system disorders. The trial will be monitored by a Data and Safety Monitoring Board (DSMB) and the trial will be discontinued in case of safety concerns."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Secondary endpoints: safety will be determined by the assessment of major adverse coronary events (MACE)."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "4 months-1year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01291329"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "Click here for more information about heart disease",
                              "Click here for more information about this study and adult mesenchymal stem cells."
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.americanheart.org",
                              "http://www.osiris.com"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00114452"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The NYHA classification is used to grade the severity of functional limitations in a patient with heart failure with Class I=no limitations to Class IV=unable to carry on any physical activity without discomfort.",
                              "MACE are defined as death, recurrent MI, stroke, target vessel revascularization.",
                              "Change of serum level of NT pro-BNP from baseline visit to subsequent visits will be summarized by descriptive statistics.",
                              "The FEV1 will be tested by Spirometry and recorded.",
                              "Change of regional left ventricular wall motion score in total score from baseline visit to subsequent visits will be displayed by descriptive statistics",
                              "Change of LVESV in mL from baseline visit to subsequent visits will be displayed by descriptive statistics",
                              "Change of LVEDV in mL from baseline visit to subsequent visits will be displayed by descriptive statistics",
                              "Change of LV fractional shortening in % from baseline visit to subsequent visits will be displayed by descriptive statistics",
                              "Change of LVEF in % from baseline visit to subsequent visits will be displayed by descriptive statistics",
                              "Change of LVEF in % from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Change of regional left ventricular wall motion score in total score from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Change of LVESV in mL from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Change of LVEDV in mL from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Change of scar volume in % from baseline visit to subsequent visits will be summarized by descriptive statistics",
                              "Change of myocardial fibrosis quantification in % from baseline visit to subsequent visits will be summarized by descriptive statistics"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "New York Heart Association (NYHA) Classification",
                              "Incidence of major adverse cardiovascular events (MACE)",
                              "Serum level of amino-terminal pro-brain natriuretic peptide (NT pro-BNP)",
                              "Pulmonary function test",
                              "Echocardiogram",
                              "Echocardiogram",
                              "Echocardiogram",
                              "Echocardiogram",
                              "Echocardiogram",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation",
                              "Cardiac MRI (cMRI) for baseline and efficacy evaluation"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 weeks",
                              "from screen visit to 12-month follow-up period",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks",
                              "52 weeks"
                        ],
                        "SeeAlsoLinkLabel": [
                              "First-in-human pilot trial of combined intracoronary and intravenous mesenchymal stem cell therapy in acute myocardial infarction"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.frontiersin.org/articles/10.3389/fcvm.2022.961920/full"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04056819"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "a test to see improvement in LVEF(%), improvement in regional function, improvement in perfusion, reduction of infarct size.",
                              "a test to see improvement in LVEF (%), improvement in regional function, improvement in perfusion, reduction of infarct size.",
                              "Left ventricular volumes will be determined at end-diastole and end-systole by quantitative biplane assessment. Endocardial borders will be manually traced from apical four-chamber and two-chamber views. Left ventricular volumes will be used to calculate ejection fraction using the biplane modified Simpson's summation-of-disks method recommended by the American Society of Echocardiography.",
                              "Left ventricular volumes will be determined at end-diastole and end-systole by quantitative biplane assessment. Endocardial borders will be manually traced from apical four-chamber and two-chamber views. Left ventricular volumes will be used to calculate ejection fraction using the biplane modified Simpson's summation-of-disks method recommended by the American Society of Echocardiography.",
                              "to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts",
                              "to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts",
                              "to detects cardiac (heart) abnormalities by measuring the electrical activity generated by the heart as it contracts",
                              "hs-CRP, antioxidant, IL-6, IL-10, PA1, Fibrinogen",
                              "Haematology, Serum Chemistry, Cardiac Biomarker"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Cardiac MRI",
                              "Cardiac MRI",
                              "Echocardiography",
                              "Echocardiography",
                              "Electrocardiography (ECG)",
                              "Electrocardiography (ECG)",
                              "Electrocardiography (ECG)",
                              "Wellness Parameter",
                              "Laboratory Assessment"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months after stem cell",
                              "12 months after stem cell",
                              "6 months after stem cell",
                              "12 months after stem cell",
                              "3 months after stem cell",
                              "6 months after stem cell",
                              "12 months after stem cell",
                              "6 months after stem cell",
                              "12 months after stem cell"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04340609"
                        ]
                  },
                  {
                        "Rank": 7,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "RU8HM86-54N"
                        ],
                        "SecondaryIdDomain": [
                              "State Research Institute of Circulation Pathology"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "comparison the number of patients with thromboembolic events between two groups"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "All-cause death",
                              "number of patients with thromboembolic events",
                              "number of heart failure hospitalizations",
                              "Distance during 6-minute walking test",
                              "number of patients with life-threatening arrhythmias",
                              "BNP level",
                              "SPECT and Echo data"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01394432"
                        ]
                  },
                  {
                        "Rank": 8,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Left ventricle ejection fraction (LVEF) measured 6 months after the cell treatment (MRI measurement)",
                              "Change in infarct size evaluated by MRI at 6 and 13 months compared to before administration",
                              "Change in left ventricular end systolic size evaluated by MRI at 6 months and 13 months compared to before administration",
                              "Change in left ventricular end diastolic size evaluated by MRI at 6 months and 13 months compared to before administration",
                              "The incidence of major cardiac events (death, hospitalization for cardiac shock or heart failure, recurrence of myocardial infarction, occurrence of severe arrhythmias) within 24 months after administration",
                              "Heart rate variability change at 13 months compared to before administration (24 hours Holter measurement)",
                              "The amount of change in the left ventricular local wall movement impairment index evaluated by echocardiography at 6 and 13 months compared to before administration",
                              "Changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) at 6 and 13 months compared to before administration"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "LVEF amount of change",
                              "Infarct size amount of change",
                              "Left ventricle end systolic size change",
                              "Left ventricular end-diastolic size change",
                              "Incidence of critical heart events",
                              "Heart rate variability change amount",
                              "Left ventricular local wall movement disorder index change",
                              "N-terminal pro-brain natriuretic peptide (NT-proBNP) change"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months after the cell treatment",
                              "6, 13 months after the cell treatment",
                              "6, 13 months after the cell treatment",
                              "6, 13 months after the cell treatment",
                              "Within 24 months after the cell treatment",
                              "13 months after the cell treatment",
                              "6, 13 months after the cell treatment",
                              "6, 13 months after the cell treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01652209"
                        ]
                  },
                  {
                        "Rank": 9,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "2018-001964-49"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "EudraCT Number"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Safety measured with a combined endpoint of serious clinical events (death or rehospitalization due to any cause) and serious adverse reactions related to the investigational treatment",
                              "Death rate or rehospitalization due to cardiovascular causes at week, 3, 6 and 12 months.",
                              "Rate of relevant arrhythmias in Holter of 24 hours a week, 3 and 12 months.",
                              "Relevant changes in NT-proBNP and hsTnI levels at week, 3 and 12 months.",
                              "Changes in the necrotic myocardial mass ratio due to gadolinium retention at 3 and 12 months.",
                              "change of regional contractility by nuclear magnetic resonance (NMR) at 3 and 12 months.",
                              "Changes in ejection fraction of the left at 3 and 12 months",
                              "changes in left and right ventricular geometric remodeling at 3 and 12 months",
                              "Changes in the score on the quality of life test SF-36 will be used at 3 and 12 months. The m\u00ednimum value is 0 and the m\u00e1ximum value is 100. Higher scores mean a better outcome.",
                              "Changes in the score on the quality of life test KCCQ in cases of participants with heart failure will be used at 3 and 12 months. The test is composed of 23 items. The options for the answers are Likert scales of 1 to 5, 6 or 7 points and the score of each of its dimensions has a theoretical range from 0 to 100, 100 being the best outcome."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Rate of death or rehospitalization due to any cause and / or adverse reactions related to the procedure / product under investigation.",
                              "Death rate or rehospitalization due to cardiovascular causes",
                              "Rate of relevant arrhythmias in Holter of 24 hours",
                              "Relevant changes in N-terminal B-type natriuretic peptide (NT-proBNP) and High sensitivity troponin I (hsTnI) levels",
                              "Changes in the necrotic myocardial mass ratio",
                              "Changes of regional contractility",
                              "Changes in ejection fraction of the left ventricle",
                              "changes in left and right ventricular geometric remodeling",
                              "Changes in the score on the quality of life test Short Form 36 Healthy Survey (SF-36).",
                              "Changes in the score on the quality of life Kansas City Cardiomyopathy Questionnaire (KCCQ) test in cases of participants with heart failure will be used."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At 1 week, 3 and 6 months",
                              "At 1 week, 3 , 6and 12 months",
                              "At 1 week, 3 and 12 months",
                              "At 1 week, 3 and 12 months",
                              "At 3 and 12 months",
                              "At 3 and 12 months",
                              "At 3 and 12 months",
                              "At 3 and 12 months",
                              "At 3 and 12 months",
                              "At 3 and 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03798353"
                        ]
                  },
                  {
                        "Rank": 10,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Regional myocardial perfusion and infarct size"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00883727"
                        ]
                  },
                  {
                        "Rank": 11,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The Duke Activity Status Index (DASI) is a brief, self-administered questionnaire that provides a standardized assessment of functional status and quality-of-life that correlates well with an objective measure of maximal exercise capacity. The scale ranges from 0 (unable to perform any tasks) to 58.20 (able to perform all tasks). Higher scores indicate a greater ability to perform daily activities."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Left Ventricular End Systolic Volume",
                              "Infarct Size",
                              "Left Ventricular Ejection Fraction",
                              "Left Ventricular End Diastolic Volume",
                              "Number of Participants with Ventricular Arrhythmias",
                              "Duke Activity Status Index (DASI) Assessment",
                              "New York Heart Association (NYHA) Congestive Heart Failure Classification Status",
                              "Maximal Symptom-limited Exercise Test (Treadmill)",
                              "Number of Participants with Major Adverse Cardiac Events (MACE)",
                              "Overall Survival",
                              "Number of Participants with Adverse Events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "3 and 6 months",
                              "3 and 6 months",
                              "3 and 6 months",
                              "3 and 6 months",
                              "6, 12, and 24 months",
                              "6, 12, 24, and 60 months",
                              "6 and 12 months",
                              "6, 12, 24, and 60 months",
                              "60 months",
                              "3,6,12,24,60 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00877903"
                        ]
                  },
                  {
                        "Rank": 12,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "measured by MRI",
                              "measured by MRI",
                              "measured by MRI",
                              "measured by MRI"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The change from baseline on physical exam conducted at 1, 3 and 6 months post-administration",
                              "LV end diastolic volume",
                              "LV end systolic volume",
                              "Infarct size measured by MRI, with contrast",
                              "Global Left Ventricular Ejection Fraction"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "3 months",
                              "3 months",
                              "3 months",
                              "3 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02672267"
                        ]
                  },
                  {
                        "Rank": 13,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Secondary end points included death from a composite of major adverse card cardiovascular events plus any coronary revascularization within 12 months.",
                              "Secondary end points included death from hospitalization for congestive heart failure within 12 months.",
                              "Secondary end points included the level change of hsCRP within 12 months."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Coronary disease",
                              "Coronary congestive heart failure",
                              "Coronary changes in hsCRP"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04551443"
                        ]
                  },
                  {
                        "Rank": 14,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03047772"
                        ]
                  },
                  {
                        "Rank": 15,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Measurement of left ventricular function with echocardiography",
                              "Occurrence of mortality due to cardiovascular causes",
                              "Occurrence of mortality due to cardiovascular causes or heart failure"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in Left Ventricular Function from base line",
                              "Cardiovascular Death",
                              "Composite outcome of cardiovascular death and heart failure incidence"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline and after six months",
                              "Checked at three years",
                              "Checked at three years"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT05043610"
                        ]
                  },
                  {
                        "Rank": 16,
                        "ResultsFirstSubmitDate": [
                              "October 19, 2017"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "January 21, 2020"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Determined by delayed contrast enhanced Computed Tomography (CT) Scan",
                              "Tissue perfusion measured by CT.",
                              "Peak VO2 assessed via treadmill determination.",
                              "A test that measures how far a patient can walk in 6 minutes.",
                              "Changed in NYHA Functional Classification will be evaluated. Worsened: Documented increase in limitation in physical activity. Improved: Documented decrease in limitation in physical activity. Unchanged: No documented change in limitation in physical activity.",
                              "Incidence of the Major Adverse Cardiac Events (MACE) endpoint, defined as the composite incidence of (1) death, (2) hospitalization for worsening heart failure, or (3) non-fatal recurrent MI.",
                              "Incidence of Treatment Emergent Adverse Event defined as any untoward medical occurrence in a patient or clinical investigation subject temporally associated with the use of the study product.",
                              "Minnesota Living with Heart Failure (MLHF) Questionnaire has a total score from 0 to 105. A higher score indicates that participant's heart failure is preventing them from living their life.",
                              "Left ventricular end diastolic wall thickness as determined by echocardiogram.",
                              "As determined by Computed Tomography Scan",
                              "As determined by Computed Tomography Scan",
                              "As determined by Computed Tomography Scan",
                              "Change in 1-year LVEF by CT as compared to baseline.",
                              "As assessed via ECHO",
                              "Difference in left ventricular end diastolic and end systolic volume will be assessed via ECHO",
                              "Difference in left ventricular end diastolic and end systolic volume will be assessed via CT",
                              "As measured via myocardial mass by CT",
                              "The number of participants with abnormal ECG readings via 24 hour ambulatory ECG recordings as assessed per treating physician discretion.",
                              "Clinical significance of abnormal lab values will be assessed by treating physician",
                              "Serial Troponin I values in ng/mL over time.",
                              "The number of participants with abnormal reading post-cardiac catheterization. As assessed per treating physician discretion.",
                              "CK-MB values in ng/mL over time."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Infarct Scar Size (ISS)",
                              "Number of Participant With Reported Tissue Perfusion",
                              "Peak Oxygen Consumption (VO2)",
                              "Six-minute Walk Test.",
                              "Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.",
                              "Number of Incidents of Major Adverse Cardiac Events (MACE).",
                              "Number of Participants With Treatment Emergent Adverse Event (AE)",
                              "Minnesota Living With Heart Failure (MLHF) Questionnaire Scores",
                              "Echocardiographic-derived Measures of Left Ventricular Function",
                              "Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)",
                              "Difference Between the Regional Left Ventricular Wall Thickening",
                              "Difference Between Left Ventricular End Diastolic Wall Thickness",
                              "Difference Between the Left Ventricular Ejection Fraction (LVEF)",
                              "Difference in LVEF",
                              "Difference in Left Ventricular Volume",
                              "Difference in Left Ventricular Volume",
                              "Difference in Left Ventricular Regional Myocardial Perfusion",
                              "Number of Participants With Abnormal Electrocardiogram (ECG) Reads.",
                              "Number of Clinically Significant of Abnormal Lab Values.",
                              "Serial Troponin I",
                              "Number of Participants With Abnormal ECHO Reading",
                              "Creatinine Kinase Muscle/Brain (CK-MB)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 12 months",
                              "6 months, 12 months",
                              "Baseline, 6 months, 12 months",
                              "Baseline, 3 months, 6 months, 12 months",
                              "Baseline to 3 months, Baseline to 6 months, Baseline to 12 months",
                              "1 month, 6 months, 12 months post injection.",
                              "6 months, 12 months",
                              "Baseline, 3 months, 6 months, 12 months",
                              "6 months, 12 months",
                              "Baseline, 12 Months",
                              "Baseline, Month 12",
                              "Baseline, 12 Months",
                              "Baseline, 12 months",
                              "Baseline, 6 months, 12 months",
                              "Baseline, 6 months, 12 months",
                              "Baseline, 12 months",
                              "Baseline, 12 months",
                              "12 months",
                              "12 months",
                              "12 hours, 24 hours post cardiac catheterization",
                              "6 hours post cardiac catheterization",
                              "12 hours, 24 hours post cardiac catheterization"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://isci.med.miami.edu"
                        ],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT02013674"
                        ]
                  },
                  {
                        "Rank": 17,
                        "ResultsFirstSubmitDate": [
                              "January 30, 2015"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "April 1, 2015"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "U54HL081028"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/U54HL081028"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Change in infarct scar size (ISS) between baseline and 6-month and 18 month visits as determined by delayed contrast-enhanced MRI.",
                              "The Left Ventricular Function differences in the region of MSC injection were evaluated. LVF is evaluated via ECHO as the percentage of ejected blood.",
                              "Difference between baseline and 18 month regional left ventricular wall thickening as determined by MRI.",
                              "Difference between the baseline and 18 month left ventricular end diastolic wall thickness as determined by MRI and echocardiogram.",
                              "Change in left ventricular end diastolic and systolic volume as determined by MRI and echocardiogram.",
                              "Change between baseline to 6-month and 18-month left ventricular ejection fraction (LVEF) as determined by MRI and echocardiogram.",
                              "Change in Peak VO2 as determined by treadmill test (mL/mg/min) from Baseline to 6 and from baseline to 18 months",
                              "Change in Six Minute Walk Test (in meters) from Baseline to 6 Months and Baseline to 18 Months",
                              "Change in New York Heart Association (NYHA) Functional Classification based on patient's self reported activity level.\n\nWorsened: documented increase in limitations of physical activity as self-described by subject Improved: documented decrease in limitations of physical activity as self-described by subject Unchanged: no documented change in limitations of physical activity as self-described by subject",
                              "Minnesota Living with Heart Failure (MLHF) questionnaire has a total score from 0 to 105. A higher score indicates that participants heart failure is preventing them from living their lives measured at two time points.",
                              "Incidence of Major Adverse Cardiac Events (MACE). A composite incidence of (1) death, (2) hospitalization for heart failure, or (3) non-fatal recurrent Ml.",
                              "Ambulatory ECG monitoring is the most widely employed technology for the evaluation of a patient with symptoms suggestive of cardiac arrhythmia or conduction abnormality.\n\nWhen the patient returns for follow up the 48- Hour Ambulatory monitor provides the data to the site staff to detect any abnormal recordings based upon standard ECG protocol.",
                              "Change in Pulmonary Function from Baseline to 6 month, Baseline to 12 month, and Baseline to 18 month visits as measured by forced expiratory volume in 1 second (FEV1)",
                              "Serial Troponin Values (ng/mL) Values from Baseline to 48 Hours Post CABG",
                              "Creatinine Kinase MB (ng/mL) Values every 12 hours from Baseline to 48 Hours Post CABG",
                              "Clinically significant laboratory values are first determined via standard laboratory normal values from a CAP and CLIA certified Laboratory and then assessed by investigator based on specific patient conditions and disease state.",
                              "Rate of Treatment Emergent Adverse Events Post Coronary Artery Bypass Graft (CABG) at 6 Months, 12 Months, and 18 Months",
                              "The number of abnormal Echocardiogram readings 2 Days Post CABG will be documented based on transthoracic Echocardiographic standards. However, although Echocardiograms 2 days post CABG operation may show abnormalities which is standard in this population, this testing is instrumental because it measures End- diastolic wall thickness and Left ventricular volumes at end-diastole and end-systole."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in Infarct Scar Size (ISS) Over 18 Month Period",
                              "Left Ventricular Function (LVF) in Region of MSC Injection",
                              "Regional Left Ventricular Wall Thickening",
                              "Left Ventricular End Diastolic Wall Thickness",
                              "Change in Left Ventricular End Diastolic and Systolic Volume",
                              "Change in Left Ventricular Ejection Fraction",
                              "Change in Peak Volume Oxygen",
                              "Change in Six Minute Walk Test",
                              "Change in NYHA Functional Class",
                              "Minnesota Living With Heart Failure Questionnaire Scores",
                              "Incidence of Major Adverse Cardiac Events (MACE)",
                              "Number of Participants With Abnormal 48-Hour Ambulatory ECG Recordings",
                              "Change in Pulmonary Function",
                              "Serial Troponin Values (ng/mL)",
                              "Creatinine Kinase - Muscle/Brain (MB) (ng/mL)",
                              "Number of Clinically Significant Laboratory Values",
                              "Rate of Treatment Emergent Adverse Events",
                              "Number of Abnormal Echocardiogram Readings 2 Days Post CABG."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 6 Months, 18 Months",
                              "Assessed at Baseline and 18 Months",
                              "Assessed at Baseline and 18 months",
                              "Assessed at Baseline and 18 months",
                              "Baseline, 6 Months, 18 Months",
                              "Baseline to 6 Months, Baseline to 18 Months",
                              "Baseline, 6 Months, 18 Months",
                              "Baseline, 6 Months, 18 Months",
                              "Baseline to 6 Months, 6 months to 18 Months",
                              "Assessed at 6 Months and 18 Months",
                              "18 Months",
                              "Assessed at 6 Months, 12 Months, and 18 Months",
                              "Baseline, 6 Months, 12 Months, 18 Months",
                              "Assessed at Baseline, 12 hours, 24 hours, 36 hours, and 48 hours post CABG",
                              "Assessed at Baseline, 12 Hours, 24 Hours, 36 Hours, and 48 hours post CABG",
                              "18 Months",
                              "Assessed at 6 Months, 12 Months, and 18 Months",
                              "Day 2"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT00587990"
                        ]
                  },
                  {
                        "Rank": 18,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "left ventricular ejection fraction measured by magnetic resonance imaging"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Difference in left ventricular ejection fraction measured by magnetic resonance imaging at baseline and 12 months follow-up"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03902067"
                        ]
                  },
                  {
                        "Rank": 19,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Infarct size reduction in SPECT.",
                              "Myocardial perfusion improvement assessed in SPECT.",
                              "Myocardial perfusion improvement assessed in cardiac MRI.",
                              "Increase of left ventricle ejection fraction (LVEF) assessed in cardiac MRI.",
                              "Increase of left ventricle ejection fraction (LVEF) assessed in SPECT.",
                              "Left ventricle ejection fraction (LVEF) change (in %) against baseline, assessed in echocardiography.",
                              "Left ventricle end-systolic volume (ESV, in ml) change against baseline, assessed in echocardiography",
                              "Left ventricle end-diastolic volume (EDV, in ml) change against baseline, assessed in echocardiography.",
                              "The occurrence of major adverse cardiovascular events (MACE including death, myocardial infarction, and hospitalization for heart failure).",
                              "Quality of life improvement, assessed by SF-36 questionnaire or other dedicated for investigated population."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Infarct size reduction",
                              "Myocardial perfusion improvement",
                              "Myocardial perfusion improvement",
                              "Increase of left ventricle ejection fraction (LVEF)",
                              "Increase of left ventricle ejection fraction (LVEF)",
                              "Left ventricle ejection fraction (LVEF) change against baseline.",
                              "Left ventricle end-systolic volume (ESV) change against baseline.",
                              "Left ventricle end-diastolic volume (EDV) change against baseline.",
                              "The occurrence of major adverse cardiovascular events",
                              "Quality of life improvement"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "6 month FU",
                              "1 year FU",
                              "6 month and 1 year FU."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03404063"
                        ]
                  },
                  {
                        "Rank": 20,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The change in THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF after the operation"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Day 0, Day 30, Day 90, Day 180, Day 360, Day 720"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04939077"
                        ]
                  },
                  {
                        "Rank": 21,
                        "ResultsFirstSubmitDate": [
                              "August 30, 2013"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "May 21, 2015"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "R01HL110737",
                              "R01HL107110",
                              "R01HL084275",
                              "P20HL101443",
                              "R01HL094849"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/R01HL110737",
                              "https://reporter.nih.gov/quickSearch/R01HL107110",
                              "https://reporter.nih.gov/quickSearch/R01HL084275",
                              "https://reporter.nih.gov/quickSearch/P20HL101443",
                              "https://reporter.nih.gov/quickSearch/R01HL094849"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract",
                              "U.S. NIH Grant/Contract",
                              "U.S. NIH Grant/Contract",
                              "U.S. NIH Grant/Contract",
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Percentage change from 13-months post-catheterization to baseline.",
                              "The Minnesota living with heart failure questionnaire uses a 6-point, zero to five, Likert scale. The total score is the sum of the 21 responses. The total score is considered the best measure of how heart failure and treatments impact a patients quality of life. The max score is 105, minimum score is 0. A lower score is considered a better quality of life."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "CT Infarct Size From Early Enhanced Defect: - Difference Between the Baseline and 13-month",
                              "CT Measure of Left Ventricular Ejection Fraction",
                              "CT Measure of End Diastolic Volume",
                              "CT Measure of End Systolic Volume",
                              "CT Measure of Scar Size as % of LV Mass",
                              "Change in Distance Walked in 6-minutes From Baseline.",
                              "Change in Minnesota Living With Heart Failure Total Score",
                              "Change in New York Heart Association Class at 12-months"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline Month 13 post-catheterization",
                              "Baseline Month 13 post-catheterization",
                              "Baseline Month 13 post-catheterization",
                              "Baseline Month 13 post-catheterization",
                              "Baseline Month 13 post-catheterization",
                              "12-months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT01087996"
                        ]
                  },
                  {
                        "Rank": 22,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "The change from baseline on physical exam conducted at day 14 and at 1, 3, 6 and 12 months post-administration, as available:",
                              "\u2022 LV end diastolic volume",
                              "\u2022 LV end systolic volume",
                              "\u2022 Infarct size measured by MRI, with and without contrast (only for patients eligible for MRI)",
                              "\u2022 Global Left Ventricular Ejection Fraction (measured by echocardiography)",
                              "\u2022 SF-36 Health Assessment",
                              "\u2022 Incidence of Ventricular Arrhythmias requiring intervention at 1 and 3 months post-administration"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01770613"
                        ]
                  },
                  {
                        "Rank": 23,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Pump failure Killip classification",
                              "New York Heart Association(NYHA) classification",
                              "Occurrence of major adverse event"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline, 1 week, 1 month, 6 month, 12 month,18 month",
                              "1 week, 1 month, 6 month, 12 month,18 month",
                              "3 day, 1 week, 1 month, 6 month, 12 month,18 month"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02666391"
                        ]
                  },
                  {
                        "Rank": 24,
                        "ResultsFirstSubmitDate": [
                              "January 17, 2014"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "November 9, 2015"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Data provided are with respect to the change from baseline at 12-months post-catheterization.",
                              "Data provided are with respect to the change from baseline at 12-months post-catheterization. The Minnesota living with heart failure questionnaire uses a 6-point, zero to five, Likert scale. The total score is the sum of the 21 responses. The total score is considered the best measure of how heart failure and treatments impact a patients quality of life. The max score is 105, minimum score is 0. A lower score is considered a better quality of life.",
                              "Data provided are with respect to the change from baseline at 12-months post-catheterization."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Serial Troponin Values (Every 12 Hours for the First 48 Hours Post-catheterization).",
                              "Serial Creatine Kinase Values (Every 12 Hours for the First 48 Hours Post-catheterization).",
                              "Incidence of the Major Adverse Cardiac Events (MACE) Endpoint, Defined as the Composite Incidence of (1) Death, (2) Hospitalization for Heart Failure, or (3) Non-fatal Recurrent MI.",
                              "Ectopic Tissue Formation.",
                              "Number of Deaths",
                              "Change From Baseline in Distance Walked in Six-minutes (Six-minute Walk Test).",
                              "Change From Baseline in the Minnesota Living With Heart Failure (MLHF) Questionnaire Total Score.",
                              "Percent Change From Baseline in Scar Mass as a Fraction of Left Ventricle Mass by Cardiac MRI or CT."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Measured every 12 hours for the first 48 hours post-catheterization",
                              "Measured every 12 hours for the first 48 hours post-catheterization",
                              "12 months post-catheterization",
                              "12 months post-catheterization",
                              "12-months post-catheterization",
                              "12 months post-catheterization",
                              "12 months post-catheterization",
                              "12 Months post-catheterization"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment",
                              "Non-systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT00768066"
                        ]
                  },
                  {
                        "Rank": 25,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The secondary end point was efficacy, which was assessed in terms of the absolute change in the global LV ejection fraction (LVEF) from baseline to 12 months post-treatment, as measured by cardiac magnetic resonance imaging (CMRI). Furthermore, CMRI assessments measured scar mass and viable myocardial mass in the left ventricle, scar size, cardiac volumes, global function, regional function, and 6-min walk tests in all patients from baseline to 12 months post-treatment."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The secondary end point was efficacy in absolute change of the global LV ejection fraction (LVEF) from baseline to 12 months by MRI"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02368587"
                        ]
                  },
                  {
                        "Rank": 26,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Rate of adverse events occurring ad",
                              "Ectopic tissue formation (as identified from MRI scans of the chest, abdomen, & pelvis).",
                              "Electrocardiogram (ECG) recordings measured over 48 Hours",
                              "Hematology value changes will be observed at the 6 month and 12 month visit post-catheterization.",
                              "Urinalysis results changes will be observed at the 6 month and 12 month visit post-catheterization.",
                              "Clinical chemistry value changes will be observed at the 6 month and 12 month visit post-catheterization.",
                              "Pulmonary function - forced expiratory volume in 1 second (FEV1) results.",
                              "Serial troponin I values (every 12 hours for first 48 hours post-cardiac catheterization).",
                              "CK-MB values (every 12 hours for first 48 hours post-cardiac catheterization).",
                              "Echocardiogram performed after cardiac catheterization",
                              "Document Infarct Scar Size (ISS) via Magnetic Resonance imaging (MRI)",
                              "Document Infarct Scar Size (ISS) via echocardiographic procedure",
                              "Document Left Regional Ventricular Function via Magnetic Resonance imaging (MRI)",
                              "Document Left Regional Ventricular Function via echocardiographic procedure",
                              "Document Global Ventricular Function via Magnetic Resonance imaging (MRI)",
                              "Document Global Ventricular Function via echocardiographic procedure",
                              "Measure Tissue Perfusion via Magnetic Resonance imaging (MRI)",
                              "Peak VO2 Oxygen Consumption determined by utilizing treadmill",
                              "Evaluate Functional Capacity via the Six Minute Walk Test",
                              "Evaluate Functional Capacity via New York Heart Association (NYHA) Class Determination",
                              "Evaluate Quality Of Life Changes via Minnesota Living with Heart Failure (MLHF) Questionnaire",
                              "Incidence of Major Adverse Cardiac Events (MACE), defined as the composite incidence of (1) death, (2) hospitalization for worsening HF, or (3) non-fatal recurrent MI."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Treatment Emergent adverse event rates",
                              "Ectopic tissue formation",
                              "48-hour ambulatory electrocardiogram (ECG) recordings.",
                              "Hematology value changes post-catheterization",
                              "Urinalysis results changes post-catheterization",
                              "Clinical chemistry values post-catheterization",
                              "Pulmonary function",
                              "Serial troponin I values",
                              "Creatine kinase-MB (CK-MB) value changes post-catheterization",
                              "Post-cardiac catheterization echocardiogram.",
                              "Magnetic resonance imaging (MRI) measures of infarct scar size (ISS)",
                              "Echocardiographic measures of infarct scar size (ISS)",
                              "Magnetic resonance imaging (MRI) of Left Regional Ventricular Function",
                              "Echocardiographic measures of Left Regional Ventricular Function",
                              "Magnetic resonance imaging (MRI) of Global Ventricular Function",
                              "Echocardiographic measures of Global Ventricular Function",
                              "Tissue perfusion measured by MRI.",
                              "Peak oxygen consumption (Peak VO2) (by treadmill determination).",
                              "Six-minute walk test.",
                              "New York Heart Association (NYHA) functional class.",
                              "Minnesota Living with Heart Failure (MLHF) questionnaire.",
                              "Incidence of Major Adverse Cardiac Events (MACE)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "Every 12 hours for the first 48 hours post-cardiac catheterization",
                              "Every 12 hours for first 48 hours post-cardiac catheterization",
                              "Day 1 Post Echocardiogram",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit",
                              "At 6 Month and 12 Month visit"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://isci.med.miami.edu"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02503280"
                        ]
                  },
                  {
                        "Rank": 27,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Change from baseline in SF-36, VO2max, 6 min walk test, and the NYHA, CCS Classifications Effect related to cardiac function"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "30 days to 2 years"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01076920"
                        ]
                  },
                  {
                        "Rank": 28,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02504437"
                        ]
                  },
                  {
                        "Rank": 29,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Myocardial scar size reduction assessed with SPECT",
                              "Myocardial scar size reduction assess with SPECT",
                              "Left ventricular ejection fraction",
                              "Quality of life evaluated with MLHFQ"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Scar reduction",
                              "Scar reduction",
                              "LVEF",
                              "Change in quality of life"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "4 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01753440"
                        ]
                  },
                  {
                        "Rank": 30,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [
                              "Mayo Clinic Clinical Trials"
                        ],
                        "SeeAlsoLinkURL": [
                              "https://www.mayo.edu/research/clinical-trials"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04388761"
                        ]
                  },
                  {
                        "Rank": 31,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The secondary end point was efficacy, which was assessed in terms of the change in low attenuation plaque volume LAPV by Coronary computed tomography angiography (coronary CTA) from baseline to 12 months.",
                              "The level of high-sensitivity C-reactive protein (hsCRP) from baseline to 12 months."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The secondary end point was measuring low attenuation plaque volume LAPV",
                              "The secondary end point was efficacy 2"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 10 months",
                              "up to 10 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04551456"
                        ]
                  },
                  {
                        "Rank": 32,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Tracking the infused cells"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Month 2 post-transplantation"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00515307"
                        ]
                  },
                  {
                        "Rank": 33,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Time from PICU admission to discharge"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "length of stay in PICU"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "up to 28 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04850469"
                        ]
                  },
                  {
                        "Rank": 34,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "as measured by serial echocardiograms and MRI scans.",
                              "Assessed through the number of participants with adverse events, hospitalizations, or transplantations.",
                              "Changes in weight, height, and head circumference will be measured",
                              "Assessment of cardiovascular mortality, all-cause morbidity, Cardiovascular morbidity, re-hospitalizations, need for transplantation."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Composite Change from baseline in right ventricular function, right ventricular end-diastolic volume, right ventricular end-systolic volume, right ventricular end-systolic diameter and tricuspid regurgitation",
                              "Number of participants with incidence of mortality or need for transplantation after the BDCPA operation",
                              "Composite Changes in somatic growth velocity over time (weight, height, head circumference) from the BDCPA operation",
                              "Assessment of Co-morbidity"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline, 24 weeks and 1 year",
                              "One year after injections",
                              "12 months post operative",
                              "up to 12 months follow-up"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Interdisciplinary Stem Cell Institute"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://isci.med.miami.edu"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02398604"
                        ]
                  },
                  {
                        "Rank": 35,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Exercise time and level as assessed via six minute walk test.",
                              "The efficacy of UC-MSC treatment was quantified by the differences between the two groups and from baseline to 6 and 12 months in perfusion images, as measured by SPECT.",
                              "Change in left ventricular ejection fraction was assessed with echocardiography after cell implantation.",
                              "The NYHA scale ranges from 1 (best)\"Mild- no limitation of physical activity due to heart failure\" to 4 (worst) \"Severe-Unable to carry out any physical activity without discomfort due to heart failure\"."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Exercise Time and Level",
                              "Quantify myocardium perfusion measured by SPECT",
                              "Assessment of heart function by left ventricular ejection fraction",
                              "Clinical Improvement in NYHA Classification"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Post cell transplantation: 1, 3, 6, 12 months",
                              "Post cell transplantation: 6, 12 months",
                              "Post cell transplantation: 1, 3, 6\uff0c12 months",
                              "1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02439541"
                        ]
                  },
                  {
                        "Rank": 36,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function. Measured by serial echocardiograms and MRI.",
                              "Used to assess change in somatic growth.",
                              "Used to assess change in somatic growth.",
                              "Used to assess change in somatic growth.",
                              "Treatment-Emergent Adverse Events will be assessed via incidence of co-morbidity, which include: cardiovascular morbidity; need for transplantation; re-hospitalizations; cardiovascular mortality; and all-cause mortality."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Efficacy: Change from baseline in right ventricular ejection fraction (%).",
                              "Efficacy: Change from baseline in right ventricular end-systolic volume.",
                              "Efficacy: Change from baseline in right ventricular end-diastolic volume.",
                              "Efficacy: Change from baseline in right ventricular end-diastolic diameter.",
                              "Efficacy: Change from baseline tricuspid regurgitation.",
                              "Efficacy: Change in weight (in kilograms).",
                              "Efficacy: Change in height (in centimeters).",
                              "Efficacy: Change in head circumference (in centimeters).",
                              "Efficacy: Number of patients with Treatment-Emergent Adverse Events, and total number of occurrences of Treatment-Emergent Adverse Events, through-out participation in trial."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03525418"
                        ]
                  },
                  {
                        "Rank": 37,
                        "ResultsFirstSubmitDate": [
                              "August 3, 2017"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "January 19, 2018"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "1R01HL110737-01"
                        ],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [
                              "https://reporter.nih.gov/quickSearch/1R01HL110737-01"
                        ],
                        "SecondaryIdType": [
                              "U.S. NIH Grant/Contract"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Measurement of Peak oxygen consumption (Peak VO2) by treadmill determination during the 12 month follow-up period.",
                              "Measurement of Six-minute walk test during the 12 month follow-up period",
                              "Measurement of regional left ventricular function, end diastolic and end systolic volume, measured by MRI, and or CT, and echocardiogram.",
                              "Measurement of New York Heart Association (NYHA) functional class during the 12 month follow-up period.",
                              "Measurement of Minnesota Living with Heart Failure (MLHF) Questionnaire during the 12 month follow-up period. It measures the effects of symptoms, functional limitations, and psychological distress on an individual's quality of life. The response scale for all 21 items on the MLHF is based on a 6-point. The Maximum possible scores being 126 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Measurement of Changes in Peak VO2",
                              "Measurement of Changes in 6 Minute Walk",
                              "Measurement of Changes in Global Ejection Fraction",
                              "Measurement of Changes in New York Heart Association (NYHA)",
                              "Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 6 month and 12 month",
                              "Baseline, 6 month and 12 month",
                              "Baseline, 6 month and 12 month",
                              "Baseline, 6 month and 12 month",
                              "Baseline, 6 month and 12 month"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Interdisciplinary Stem Cell Institute University of Miami"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://isci.med.miami.edu"
                        ],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT01392625"
                        ]
                  },
                  {
                        "Rank": 38,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "U1111-1169-2289"
                        ],
                        "SecondaryIdDomain": [
                              "Universal Trial Number"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "Rejection will be determined as biopsy-proven allograft rejection (BPAR). Graft loss will be counted when the patient loses kidney function to the point that they require chronic renal replacement therapy (e.g., dialysis for more than 8 weeks or a re-transplant)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants without any acute rejection, graft loss, or death at 6 months post transplant."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months post transplant"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03478215"
                        ]
                  },
                  {
                        "Rank": 39,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Recovery of the estimated functional status according to the New York Heart Association (NYHA) classification",
                              "Change in the median score for quality of life of the Minnesota Living with Heart Failure Questionnaire (MLHFQ)",
                              "Changes in the delayed enhancement of the left ventricle on MRI, defined as percentage of the wall thickness involved when adding each segment visually",
                              "Improvement in the 6-minute walk test, defined as the percentage of change of the distance traveled",
                              "Mortality at 3 and 12 months due to cardiovascular causes",
                              "Mortality at 3 and 12 months due to all causes"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Estimated functional status",
                              "Change in the median score of Quality of life",
                              "Delayed enhancement of the left ventricle",
                              "Improvement in the 6-minute walk test",
                              "Mortality at 3 and 12 months due to cardiovascular causes",
                              "Mortality at 3 and 12 months due to all causes"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months",
                              "12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04011059"
                        ]
                  },
                  {
                        "Rank": 40,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Changes in functional status",
                              "Improvement in other LV parameters as assessed by echocardiogram and cardiovascular magnetic resonance(CMR).",
                              "Resolution of scar tissue volume/area on cardiac MRI",
                              "Change in serum N Terminal-pro B type natriuretic peptide(NT-proBNP)level",
                              "Freedom from major adverse cardiac events as defined by myocardial infarction, hospitalization for angina, myocardial infarction or heart failure, or death (all cause of mortality)."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "12 months",
                              "1 months, 3 months, 6 months, 9 months, 12 months",
                              "6 months, 12 months.",
                              "1 month, 6 months, 12 months",
                              "1 month, 3 months, 6 months, 9 months, 12 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01720888"
                        ]
                  },
                  {
                        "Rank": 41,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Does a bone marrow transplantation therapy increase any cardiac function parameter measured by a an echocardiography, MRI or PET ischemia area, when compared with no treatment group?",
                              "Does a bone marrow transplantation therapy improve BNP-value?",
                              "Does a bone marrow transplantation therapy decrease hospitalization or the days stayed in hospital?",
                              "Does pericardial fluid growth factor concentrations correlate to left ventricular function improvement?",
                              "Does autologous cardiac stem cell quality correlate to left ventricular function improvement?"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months and 1 year after the procedure",
                              "3kk, 6 months and 1 year after the procedure",
                              "primary hospital stay after the transplantation",
                              "up to 1 year after the translantation",
                              "3kk, 6 months and 1 year after the transplantation"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT00418418"
                        ]
                  },
                  {
                        "Rank": 42,
                        "ResultsFirstSubmitDate": [
                              "April 9, 2013"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "April 23, 2015"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Changes in Exercise Capacity",
                              "Changes in Electrophysiologic Properties of Ventricular Myocardium",
                              "Changes in Plasma Inflammatory Markers",
                              "Changes in Left Ventricular Function"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "5 years",
                              "6 months",
                              "6 months",
                              "5 years"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT00629018"
                        ]
                  },
                  {
                        "Rank": 43,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02323477"
                        ]
                  },
                  {
                        "Rank": 44,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Doppler study of the endometrial blood flow; the VI, FI and VFI and 3D-US assessment of endometrial volume in all groups at the day of embryo transfer to obtain objective assessment of the effect of differentiated and undifferentiated stem cell therapy on endometrial volume and vascularity in ICSI patients with advanced maternal age or history of repeated implantation failure."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Endometrial volume and vascularity"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01649752"
                        ]
                  },
                  {
                        "Rank": 45,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [
                              "NCI-2016-01921",
                              "2015-0835"
                        ],
                        "SecondaryIdDomain": [
                              "CTRP (Clinical Trial Reporting Program)",
                              "M D Anderson Cancer Center"
                        ],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [
                              "Registry Identifier",
                              "Other Identifier"
                        ],
                        "SecondaryOutcomeDescription": [
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons.",
                              "As regards statistical analyses, the results of the trial will be displayed in table format. Will provide confidence intervals of the differences in change from baseline between each investigational group and the control group. If both investigation groups are significant at the p < .05 level, then the two investigational drugs can be compared using a gatekeeping procedure. These intervals and the associated p-values will be calculated using two-sample t-tests, with no adjustments for multiple comparisons."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in improvement of left ventricular (LV) systolic function as assessed by LVEF",
                              "LV end-systolic and end-diastolic volumes as determined by contrast-enhanced 2-dimensional(D)/3D echography",
                              "Cardiac death",
                              "Re-hospitalization after heart failure",
                              "Aborted death from an automatic implantable cardioverter defibrillator (AICD) firing",
                              "Nonfatal myocardial infarction",
                              "Revascularization"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months",
                              "Up to 6 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "MD Anderson Cancer Center"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.mdanderson.org"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02962661"
                        ]
                  },
                  {
                        "Rank": 46,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "A secondary objective will be the changes from baseline to 6 months post-treatment in the distance walked as measured by the 6-minute walk test.",
                              "A secondary objective will be the change in quality of life in patients treated with bone marrow derived mesenchymal stem cells compared to placebo using the Minnesota Living with Heart Failure Questionnaire (MLHFQ).",
                              "A secondary objective will be the change from baseline to Month 6 in NYHA Classification in patients treated with BMMSCs compared to placebo.",
                              "A secondary objective will be the overall safety and tolerability of BMMSCs versus placebo in patients with ICM from time of cell-infusion through 6 months post-treatment follow-up by the percentage of patients with adverse events.",
                              "A secondary objective will be the changes from baseline to 6 months post-treatment in the exercise time as measured by the cardiopulmonary exercise test.",
                              "A secondary objective will be the change in quality of life in patients treated with bone marrow derived mesenchymal stem cells compared to placebo using the Kansas City Cardiomyopathy Questionnaire (KCCQ)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change from baseline to 6 months follow-up in exercise distance increment",
                              "Change from baseline to 6 months follow-up in quality of life measured by MLHFQ",
                              "Change from baseline to 6 months follow-up in NYHA Classification.",
                              "Percent of patients with adverse events.",
                              "Change from baseline to 6 months follow-up in exercise time increment.",
                              "Change from baseline to 6 months follow-up in quality of life measured by KCCQ"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months",
                              "6 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03397095"
                        ]
                  }
            ]
      }
}